TEMPEST THERAPEUTICS INC (TPST) Stock Price & Overview
NASDAQ:TPST • US87978U2078
Current stock price
The current stock price of TPST is 1.52 USD. Today TPST is down by -12.14%. In the past month the price decreased by -31.53%. In the past year, price decreased by -80.96%.
TPST Key Statistics
- Market Cap
- 20.064M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.05
- Dividend Yield
- N/A
TPST Stock Performance
TPST Stock Chart
TPST Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TPST. When comparing the yearly performance of all stocks, TPST is a bad performer in the overall market: 97.36% of all stocks are doing better.
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. The financial health of TPST is average, but there are quite some concerns on its profitability.
TPST Earnings
TPST Forecast & Estimates
7 analysts have analysed TPST and the average price target is 11.22 USD. This implies a price increase of 638.16% is expected in the next year compared to the current price of 1.52.
TPST Groups
Sector & Classification
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -10.05. The EPS increased by 50.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210.49% | ||
| ROE | -568.14% | ||
| Debt/Equity | 0 |
TPST Ownership
TPST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.36 | 376.832B | ||
| AMGN | AMGEN INC | 15.29 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.36 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.67 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.7 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 11.79 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
IPO: 2012-10-04
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 24
Phone: 13026587581
TEMPEST THERAPEUTICS INC / TPST FAQ
What does TPST do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
What is the stock price of TEMPEST THERAPEUTICS INC today?
The current stock price of TPST is 1.52 USD. The price decreased by -12.14% in the last trading session.
What is the dividend status of TEMPEST THERAPEUTICS INC?
TPST does not pay a dividend.
What is the ChartMill technical and fundamental rating of TPST stock?
TPST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of TPST stock?
TEMPEST THERAPEUTICS INC (TPST) has a market capitalization of 20.06M USD. This makes TPST a Nano Cap stock.
What is the next earnings date for TPST stock?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2026-05-11, after the market close.